Presynaptic striatal dopaminergic function in atypical parkinsonisms: A meta-analysis of imaging studies.

Presynaptic striatal dopaminergic function in atypical parkinsonisms: A meta-analysis of imaging studies.

Publication date: Apr 12, 2019

Background: Multiple system atrophy (MSA), progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS) have overlapping signs and symptoms with Parkinson’s disease (PD), and these similarities complicate their clinical diagnostics. Although presynaptic dopaminergic brain imaging with PET and SPECT is clinically widely used for patients with suspected PD, the benefit of functional imaging in atypical parkinsonism syndromes remains unclear. We compared striatal presynaptic dopaminergic function in MSA parkinsonism variant (MSA-P), MSA cerebellar variant (MSA-C), PSP, CBS and PD using combined quantitative data from all published studies. Methods: PubMed database was searched from inception to August 2018 for terms “dopamine” OR “dopaminergic” AND “PET” OR “SPECT” OR “SPET” and keywords related to PD, MSA, PSP and CBS. A total of 1711 publications were identified. PET or SPECT studies comparing patients with atypical parkinsonism to another diagnostic group (PD, MSA, PSP or CBS) were included. Tracers for dopamine transporter (DAT), aromatic amino acid decarboxylase (AADC) or vesicular monoamine type 2 (VMAT2) were investigated. Tracer binding data were extracted from the original articles. Heterogeneity of the data were examined using I2 statistics and a random effect model was used to summarize data. Hedges g was used as an estimator of effect size in group comparisons. Results are reported according to PRISMA guidelines. Results: Thirty-five studies (29 DAT, 6 AADC, no VMAT2 studies) with 356 MSA-P patients, 204 PSP patients, 79 CBS patients and 62 MSA-C patients were included in the meta-analysis. Caudate nucleus and putamen DAT functions were clearly lower in PSP as compared to PD (caudate: 34.1% difference, g=-1.08, 95%CI= -1.52 to -0.64; putamen: 18.2% , g=-0.86, 95%CI=-1.50 to -0.21) and MSA-P (striatum: 31.4%, g=-0.70, 95%CI=-1.21 to -0.19), and in MSA-P as compared to MSA-C (striatum: 46.0%, g=1.46, 95%CI=0.23 to 2.68). Although not significant due to limited data, aromatic L-amino acid decarboxylase (AADC) results paralleled the DAT findings. Conclusion: Striatal presynaptic DAT function is clearly lower in PSP patients as compared to PD and MSA-P patients, and in MSA-P patients as compared to MSA-C patients.

, Kaasinen, Kankare, T., Joutsa, J., and Vahlberg, T. Presynaptic striatal dopaminergic function in atypical parkinsonisms: A meta-analysis of imaging studies. 20454. 2019 J Nucl Med.

Concepts Keywords
Amino Acid Striatum
Aromatic Caudate nucleus
Atypical Parkinsonism Putamen
Brain Imaging Multiple system atrophy
Caudate Phenethylamines
Caudate Nucleus Neurotransmitter transporters
CBS Amphetamine
Cerebellar Dopamine
DAT Basal ganglia
Dopamine Brain
Dopamine Transporter Organ systems
Dopaminergic Branches of biology
Estimator MSA parkinsonism
Functional Imaging
Meta Analysis
Monoamine
Multiple System Atrophy
Parkinson
Parkinsonism
PET
Presynaptic
Progressive
PSP
PubMed
Putamen
SPECT
SPET
Striatal
Striatum
Supranuclear Palsy
Vesicular
VMAT2

Semantics

Type Source Name
gene UNIPROT SLC18A2
gene UNIPROT DDC
gene UNIPROT SLC6A3
drug DRUGBANK Dopamine
gene UNIPROT CBS
gene UNIPROT CBSL
disease DOID syndrome
disease MESH syndrome
gene UNIPROT MSMB
gene UNIPROT REG1A
gene UNIPROT PSPN
gene UNIPROT BPIFA2
gene UNIPROT RIDA
gene UNIPROT PSPH
gene UNIPROT STXBP3
disease MESH PSP
disease DOID progressive supranuclear palsy
disease MESH progressive supranuclear palsy
gene UNIPROT TPO
disease DOID Multiple system atrophy
disease MESH Multiple system atrophy

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *